Loading stock data…
$1.28-0.01 (-0.77%)
NovaBridge Biosciences, a biotechnology company, engages in the research and development of immuno-oncology agents for the treatment of cancer in the United States.
NovaBridge Biosciences in the Healthcare sector is trading at $1.29 with a market capitalization of $185M. Wall Street consensus targets $9.00 (2 analysts), implying a +595.0% move over the next 12 months. The stock is currently near its 52-week low of $1.26, remaining 44.7% below its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: RSI 26 is oversold, raising the odds of a near-term bounce. The Whystock Score of 35/100 signals elevated caution as multiple indicators diverge.
| Metric (USD) | Q2 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | — | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | — | -$72.90M↓ | -$8.99M↓ | -$7.11M↓ | -$5.27M |
| Net Income | — | -$30.79M↓ | -$6.83M↓ | -$5.50M↓ | -$3.15M |
NovaBridge Biosciences, a biotechnology company, engages in the research and development of immuno-oncology agents for the treatment of cancer in the United States. The company operates through two segments, Oncology and Ophthalmology. Its product pi...